Sunshine Biopharma Inc
Sunshine Biopharma Inc (ticker: SBFM) is a micro‑capitalisation biotechnology company. With a market capitalisation around $8.75m, it is likely a small, development‑stage firm where investor outcomes hinge on drug‑development progress, regulatory decisions, partnerships and access to capital. Shares can be thinly traded and prone to sharp swings on trial readouts, licensing news or fundraising announcements. Common risks include limited cash runway, the binary nature of clinical results, regulatory uncertainty and potential dilution from new equity issues. Potential upside exists if programmes advance or strategic deals are struck, but such outcomes are uncertain and not guaranteed. This summary is for general, educational purposes only and is not personalised investment advice; investors should review company filings, consider their risk tolerance and seek independent financial advice as appropriate.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Sunshine Biopharma's stock with a target price of $300, indicating significant potential growth.
Financial Health
Sunshine Biopharma is showing solid revenue and cash flow, indicating a healthy business performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring SBFM
Analyst All-Stars
Take advantage of Wall Street's collective wisdom with this portfolio of top-rated stocks. These companies have earned strong 'Buy' ratings from respected financial analysts because of their solid fundamentals and potential for market outperformance.
Published: June 18, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Binary Clinical Catalysts
Trial readouts and regulatory milestones can drive large price moves; outcomes can be binary and uncertain, so performance may vary.
Financing & Dilution
Small biotechs often require additional capital. Monitor cash runway and fundraising terms, as new financing can dilute existing holders.
Partnership Potential
Collaborations or licensing deals with larger firms can materially change prospects, though they depend on positive data and successful negotiations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
